Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From David Wallace
Alvogen’s inter partes review petition challenging a Revlimid patent in the US has been denied by the PTAB, following similar denials of petitions by Dr Reddy’s over three other Revlimid patents.
The UK’s competition regulator will not take action against MSD over a suspected anti-competitive discount scheme for Remicade (infliximab), despite an earlier provisional finding that MSD had a dominant market position and the scheme was in breach of competition law.
An interim report on implementing national pharmacare in Canada that highlights the importance of cost savings and access to medicines has been welcomed by local off-patent industry body the CGPA.
Off-patent industry association Medicines for Europe is one of several European pharmaceutical associations to have lent their backing to the latest European Commission strategic approach to pharmaceuticals in the environment.
Australia’s GBMA industry association will seek to promote biosimilars through a dedicated ‘Biosimilar Week’ in late April and early May this year, running as part of a three-year education program being pursued by the association and industry stakeholders.